Cathay Biotech

About:

Cathay is a global technology leader in synthetic biology and the use of bio-processes to produce new materials on an industrial scale.

Website: http://www.cathaybiotech.com/en/

Top Investors: New Enterprise Associates, HBM Healthcare Investments

Description:

Cathay Biotech is a global technology leader in synthetic biology and the use of bio-processes to produce new materials on an industrial scale. Cathay’s long chain diacids are a perfect example demonstrating the potential for renewable bio-manufacturing to commercially displace traditional chemical processes. Cathay also developed and became the first commercial producer of pentanediamine from renewable materials. Having the two key monomers to produce polyamides, Cathay also is a global innovator in the commercialization of new and unique renewable polyamides for the engineering polymer and textile markets. As a game-changing production technology, bio-production starts with biomass and other raw materials for biological conversion to higher value products. The nature of bio-production requires environmentally friendly and mild conditions that are inherently economical. The goal of Cathay’s synthetic biology development programs is to address the excessive dependence of humans on traditionally produced chemicals as well as the subsequent environmental damage and worker safety issues associated with their production. Cathay’s headquarters and R&D are located within Zhangjiang Hi-Tech park in Shanghai, P.R. China and the two production sites are in Jinxiang, Shandong Province, and Wusu, Xinjiang Province, also in China.